Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

▤ Summary

Evogene announced a major milestone in its collaboration with Google Cloud for ChemPass AI. The company integrated agentic computational systems into its platform to help identify target product profile requirements earlier in small-molecule discovery. The upgrade aims to speed discovery, improve scalability, and raise the odds of success by profiling biological, chemical, clinical, and commercial criteria sooner. The release positions Google Cloud’s AI stack as the infrastructure behind a more autonomous life sciences discovery workflow. This matters to teams working in AI, cloud, and pharma software because it signals a deeper commercialization path for agentic AI in drug discovery.

▦ Linked Companies

Google LLC

$100M to $250M

Evogene

$1M to $5M